KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $3.1 million.

  • Bionano Genomics' Cash & Equivalents fell 6474.87% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 6474.87%. This contributed to the annual value of $9.2 million for FY2024, which is 4889.12% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Cash & Equivalents is $3.1 million, which was down 6474.87% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Cash & Equivalents registered a high of $362.1 million during Q1 2021, and its lowest value of $3.1 million during Q3 2025.
  • Its 5-year average for Cash & Equivalents is $56.3 million, with a median of $15.8 million in 2024.
  • In the last 5 years, Bionano Genomics' Cash & Equivalents skyrocketed by 434621.81% in 2021 and then crashed by 9335.87% in 2022.
  • Over the past 5 years, Bionano Genomics' Cash & Equivalents (Quarter) stood at $24.6 million in 2021, then crashed by 79.28% to $5.1 million in 2022, then surged by 252.54% to $17.9 million in 2023, then plummeted by 48.89% to $9.2 million in 2024, then crashed by 66.21% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.6 million for Q2 2025, and $3.6 million during Q1 2025.